Cartesian Therapeutics, Inc.
RNAC
$11.18
$1.6617.44%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
4/9/2025
-
Tickeron - Technical Analysis
4/9/2025
-
TipRanks Financial Blog
4/8/2025
-
Tickeron - Stocks
4/8/2025
-
GuruFocus
4/8/2025
-
The Fly
4/8/2025
-
Globe Newswire
4/5/2025
-
Tickeron - Stocks
4/5/2025
-
Tickeron - Stocks
4/4/2025
-
Tickeron - Stocks
4/3/2025
-
Tickeron - Stocks
4/2/2025
-
GuruFocus
4/2/2025
-
TipRanks Financial Blog
4/2/2025
-
The Fly
4/2/2025
-
Globe Newswire
4/1/2025
-
Tickeron - Stocks
4/1/2025
-
Tickeron - Stocks
4/1/2025
-
GuruFocus
4/1/2025
-
Globe Newswire
4/1/2025
-
MarketBeat
3/30/2025
-
24/7 Wall St.
Cartesian Therapeutics (RNAC, $14.54) Stochastic Oscillator left the oversold zone on March 28, 2025
3/29/2025
-
Tickeron - Stocks
3/29/2025
-
Tickeron - Stocks
3/28/2025
-
Tickeron - Technical Analysis
3/28/2025
-
Tickeron - Technical Analysis
3/27/2025
-
Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 13, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
301 348 8698
Address
7495 New Horizon Way
Frederick, MD 21703
Frederick, MD 21703
Country
Year Founded
--
Business Description
Sector
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product...
more
